Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine Extension Study
NCT03603964Phase 2Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Oct 2021
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Astex Pharmaceuticals. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events. Started Jul 2018; status: terminated.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03603964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603964.